The use of biologic and systemic agents for psoriasis treatment in the United States increased significantly from 2007 to 2016, according to study data published in the Journal of Dermatological Treatment.
Investigators abstracted data from the US National Ambulatory Medical Care Survey (NAMCS) from 2007 to 2016. Conducted annually since 1989, the NAMCS captures patient visit data from ambulatory sites, including diagnostic codes, patient symptoms, and medication use. Visits for which the primary, secondary, or tertiary diagnosis was psoriasis were analyzed for mention of systemic or biologic medications. Systemic medications of interest included oral small molecule inhibitors, methotrexate acitretin, and apremilast; biologic agents of interest were etanercept, infliximab, adalimumab, certolizumab, ustekinumab, and secukinumab. The percentage of visits mentioning systemic or biologic treatment was computed across patient demographic groups and survey years. Logistic regression was used to assess trends in medication use over time. Analyses were weighted to produce nationally representative estimates.
Data from 20 (95% CI, 19-21) million office visits were assessed. The most commonly represented age strata were 40 to 49 years (19%; 95% CI, 15%-23%), 50 to 59 years (24%; 95% CI, 19%-28%), and 60 to 69 years (20%; 95% CI, 16%-24%). The majority of patients (92%; 95% CI, 85%-98%) were white, and 51% (95% CI, 45%-57%) were women. Systemic Read More